Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

Humanity Protocol H token hack drains $30M, then mints 100M H

Humanity Protocol’s H token hack sent the token crashing...

Is Bitcoin a better investment than gold right now?

There is the theoretical possibility that at this precise...

Meta Platforms Stock Drops as AI Spending Fears Erase a 57% Earnings Beat

Meta Platforms stock trades near $585, sitting below all...

Oracle Stock: Wall Street Sees $330 but Sellers Control the Tape

Oracle stock enters earnings week at a critical juncture....

Alibaba Stock Slips Below Key Averages as Pentagon Blacklist Weighs

Alibaba stock faces mounting pressure as it trades at...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.